Analyze the information and social media posts to determine if the closing price of $amgn will ascend or descend at 2017-05-10. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-04-26,0.6,0.6,-0.2,-0.1,-0.1,-1.0,-1.3,-1.3,-1.0,-0.7,0.3
2017-04-27,-1.6,0.4,-1.7,-1.1,-1.1,0.2,-0.2,-0.1,0.1,0.3,1.1
2017-04-28,-0.6,0.1,-1.1,0.4,0.4,0.2,-0.5,-0.4,-0.3,-0.1,0.4
2017-05-01,0.7,1.1,-0.1,-0.4,-0.4,0.6,0.0,-0.0,0.1,0.3,0.7
2017-05-02,0.3,0.3,-0.7,0.5,0.5,-0.1,-0.4,-0.5,-0.5,-0.3,0.0
2017-05-03,0.0,0.2,-0.5,0.2,0.2,-0.4,-0.4,-0.7,-0.7,-0.5,-0.2
2017-05-04,-0.1,0.3,-0.5,0.3,0.3,-0.5,-0.6,-0.9,-0.9,-0.8,-0.6
2017-05-05,0.6,0.6,-0.8,-0.3,-0.3,-0.1,-0.1,-0.6,-0.6,-0.5,-0.3
2017-05-08,0.4,0.5,-0.3,-0.5,-0.5,0.4,0.4,-0.0,-0.1,-0.1,0.1
2017-05-09,-0.0,0.5,-0.2,0.1,0.1,0.3,0.2,-0.1,-0.2,-0.2,-0.1

2017-04-26: amgen inc. 2017 q1 - results - earnings call slides  $amgn|rt AT_USER $amgn's repeated insistence that it's committed to erenumab is somewhat undercut by tony hooper's inability to pronounce it|market
2017-04-27: rt AT_USER balanced take on rnai approach in current drug development landscape by $amgn's sean harper, this should also apply to $md¡­|will $amgn &amp; #sandoz court battle over 'patent-dance' when m
2017-04-28: also of note, validates ceo anzalone's depiction of fast moving pre-clinical work delineates $amgn collaboration w/¡­ |fy2018 eps estimates for amgen, inc. decreased by william blair $amgn |fy2018 eps
2017-04-29: $amgn max pain = 162.50. maturity = 05/05/2017. previous close = 163.32.   |rt AT_USER maoxian &gt; dirty dozen portfolio, 4/17  | my view $aapl $amzn $amgn $cmg $fb $gild $goog $nflx $nvda $sb¡­|maox
2017-04-30: $amgn max pain is 162.50 for maturity 05/05/2017. prev close = 163.32.   |$amgn, $nvs tweak partnership on migraine drug |$biib 32% roe is way above other major biotech companies $pfe $amgn $mrk $jnj 
2017-05-01: also: $nbix, $endp (pretty dramatically), $acad, $icpt, $ions. but laggards include $biib, $celg, $amgn. this is why folks missing move.| &lt; review of this fantastic traders teaching service!! try i
2017-05-02: analysts expect amgen, inc. $amgn to announce $3.09 earnings per share |zacks: analysts anticipate amgen, inc. $amgn will post quarterly sales of $5.67 billion |zacks: analysts anticipate amgen, inc. 
2017-05-03: rt AT_USER vp r&amp;d sean harper plural &amp; subtle mention (targets) i.e. ~future collab w/ $arwr during $amgn 4/26 cc AT_USER |AT_USER hey mud, $arwr likely more proficient now, along w/ the addit
2017-05-04: rt AT_USER are new bone drugs from amgen and radius cost-effective? not even close, icer says  $amgn|are new bone drugs from amgen and radius cost-effective? not even close, icer says  $amgn|helpful a
2017-05-05: fy2018 eps estimates for amgen, inc. increased by jefferies group $amgn  #acn|fy2018 eps estimates for amgen, inc. increased by jefferies group $amgn |fy2018 eps estimates for amgen, inc. increased by
2017-05-06:  &lt; review of this fantastic traders teaching service!! try it for free! $lly $dgx $mrk $nvs $amgn|$amgn max pain = 162.50. maturity = 05/12/2017. previous close = 163.81.   |AT_USER $amgn study met
2017-05-07: amgen, inc. $amgn shares sold by woodstock corp |rt AT_USER amgen: finally a good buy?  $abbv $amgn|renaissance investment group llc maintains stake in amgen, inc. $amgn |renaissance investment group 
2017-05-08: fy2018 eps estimates for amgen, inc. cut by analyst $amgn |rt AT_USER talking $fb $aapl $tsla $amgn $disck tps strategy review with AT_USER and AT_USER at 6pm et |fy2017 eps estimates for amgen, inc. 
2017-05-09: rt AT_USER AT_USER awesome battle today!i was really impressed by both $amgn &amp; $omi increased earnings &amp;cash flows &amp; eps during¡­|rt AT_USER AT_USER awesome battle today!i was really impre
Answer:
Analyze the information and social media posts to determine if the closing price of $amgn will ascend or descend at 2017-05-10. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-04-26,0.6,0.6,-0.2,-0.1,-0.1,-1.0,-1.3,-1.3,-1.0,-0.7,0.3
2017-04-27,-1.6,0.4,-1.7,-1.1,-1.1,0.2,-0.2,-0.1,0.1,0.3,1.1
2017-04-28,-0.6,0.1,-1.1,0.4,0.4,0.2,-0.5,-0.4,-0.3,-0.1,0.4
2017-05-01,0.7,1.1,-0.1,-0.4,-0.4,0.6,0.0,-0.0,0.1,0.3,0.7
2017-05-02,0.3,0.3,-0.7,0.5,0.5,-0.1,-0.4,-0.5,-0.5,-0.3,0.0
2017-05-03,0.0,0.2,-0.5,0.2,0.2,-0.4,-0.4,-0.7,-0.7,-0.5,-0.2
2017-05-04,-0.1,0.3,-0.5,0.3,0.3,-0.5,-0.6,-0.9,-0.9,-0.8,-0.6
2017-05-05,0.6,0.6,-0.8,-0.3,-0.3,-0.1,-0.1,-0.6,-0.6,-0.5,-0.3
2017-05-08,0.4,0.5,-0.3,-0.5,-0.5,0.4,0.4,-0.0,-0.1,-0.1,0.1
2017-05-09,-0.0,0.5,-0.2,0.1,0.1,0.3,0.2,-0.1,-0.2,-0.2,-0.1

2017-04-26: amgen inc. 2017 q1 - results - earnings call slides  $amgn|rt AT_USER $amgn's repeated insistence that it's committed to erenumab is somewhat undercut by tony hooper's inability to pronounce it|market
2017-04-27: rt AT_USER balanced take on rnai approach in current drug development landscape by $amgn's sean harper, this should also apply to $md¡­|will $amgn &amp; #sandoz court battle over 'patent-dance' when m
2017-04-28: also of note, validates ceo anzalone's depiction of fast moving pre-clinical work delineates $amgn collaboration w/¡­ |fy2018 eps estimates for amgen, inc. decreased by william blair $amgn |fy2018 eps
2017-04-29: $amgn max pain = 162.50. maturity = 05/05/2017. previous close = 163.32.   |rt AT_USER maoxian &gt; dirty dozen portfolio, 4/17  | my view $aapl $amzn $amgn $cmg $fb $gild $goog $nflx $nvda $sb¡­|maox
2017-04-30: $amgn max pain is 162.50 for maturity 05/05/2017. prev close = 163.32.   |$amgn, $nvs tweak partnership on migraine drug |$biib 32% roe is way above other major biotech companies $pfe $amgn $mrk $jnj 
2017-05-01: also: $nbix, $endp (pretty dramatically), $acad, $icpt, $ions. but laggards include $biib, $celg, $amgn. this is why folks missing move.| &lt; review of this fantastic traders teaching service!! try i
2017-05-02: analysts expect amgen, inc. $amgn to announce $3.09 earnings per share |zacks: analysts anticipate amgen, inc. $amgn will post quarterly sales of $5.67 billion |zacks: analysts anticipate amgen, inc. 
2017-05-03: rt AT_USER vp r&amp;d sean harper plural &amp; subtle mention (targets) i.e. ~future collab w/ $arwr during $amgn 4/26 cc AT_USER |AT_USER hey mud, $arwr likely more proficient now, along w/ the addit
2017-05-04: rt AT_USER are new bone drugs from amgen and radius cost-effective? not even close, icer says  $amgn|are new bone drugs from amgen and radius cost-effective? not even close, icer says  $amgn|helpful a
2017-05-05: fy2018 eps estimates for amgen, inc. increased by jefferies group $amgn  #acn|fy2018 eps estimates for amgen, inc. increased by jefferies group $amgn |fy2018 eps estimates for amgen, inc. increased by
2017-05-06:  &lt; review of this fantastic traders teaching service!! try it for free! $lly $dgx $mrk $nvs $amgn|$amgn max pain = 162.50. maturity = 05/12/2017. previous close = 163.81.   |AT_USER $amgn study met
2017-05-07: amgen, inc. $amgn shares sold by woodstock corp |rt AT_USER amgen: finally a good buy?  $abbv $amgn|renaissance investment group llc maintains stake in amgen, inc. $amgn |renaissance investment group 
2017-05-08: fy2018 eps estimates for amgen, inc. cut by analyst $amgn |rt AT_USER talking $fb $aapl $tsla $amgn $disck tps strategy review with AT_USER and AT_USER at 6pm et |fy2017 eps estimates for amgen, inc. 
2017-05-09: rt AT_USER AT_USER awesome battle today!i was really impressed by both $amgn &amp; $omi increased earnings &amp;cash flows &amp; eps during¡­|rt AT_USER AT_USER awesome battle today!i was really impre
Answer:+Fall